Investment Thesis
Cumberland Pharmaceuticals exhibits revenue growth momentum of 17.6% YoY and positive free cash flow, suggesting some commercial viability. However, the company faces material challenges: severe operating losses (-34.3% margin), tightening liquidity (current ratio 0.95x), and a revenue base of only $9.1M insufficient to support its cost structure, raising sustainability concerns.
Strengths
- Revenue growth of 17.6% YoY demonstrates market acceptance and commercial traction
- Positive operating cash flow of $387K despite significant net losses
- Zero long-term debt eliminates refinancing and financial leverage risks
- Cash position of $11.0M provides near-term operational runway
- Improving EPS trend (+58.7% YoY indicates some cost management progress)
Risks
- Operating margin of -34.3% and net margin of -36.0% indicate fundamental unprofitability
- Current ratio of 0.95x signals liquidity stress with current liabilities exceeding current assets
- Extremely small revenue base of $9.1M may be insufficient to achieve operating leverage
- Negative ROE (-15.2%) and ROA (-4.6%) demonstrate poor capital efficiency
- Narrow FCF margin of 4.2% provides minimal buffer against operational deterioration
Key Metrics to Watch
- Timeline to operating profitability and gross margin trends
- Current ratio and working capital management for liquidity sustainability
- Revenue growth trajectory and customer concentration
- Operating expense reduction initiatives and burn rate
- Cash runway duration and funding requirements
Financial Metrics
Revenue
9.1M
Net Income
-3.3M
EPS (Diluted)
$-0.22
Free Cash Flow
387.0K
Total Assets
71.0M
Cash
11.0M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-34.3%
Net Margin
-36.0%
ROE
-15.2%
ROA
-4.6%
FCF Margin
4.2%
Balance Sheet & Liquidity
Current Ratio
0.95x
Quick Ratio
0.79x
Debt/Equity
0.00x
Debt/Assets
70.0%
Interest Coverage
-36.46x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-09T08:17:04.589410 |
Data as of: 2026-03-31 |
Powered by Claude AI